MK-677 (ibutamoren) is a non-peptide, orally-active ghrelin-receptor agonist. It is the most-cited oral GH secretagogue and is studied for sustained…
Orally-active small-molecule ghrelin-receptor agonist studied for sustained GH/IGF-1 elevation.
MK-677 (ibutamoren) is a non-peptide, orally-active ghrelin-receptor agonist. It is the most-cited oral GH secretagogue and is studied for sustained increases in GH and IGF-1 over 24-hour windows.
MK-677 is technically a small molecule (not a peptide) that mimics ghrelin at the GHS-R1a receptor. Its oral availability and long duration of action have made it a research staple for sustained GH elevation studies.
Non-peptide ghrelin mimetic — selective agonist at GHS-R1a, producing sustained GH and IGF-1 elevation across the dosing interval.
| Property | Detail |
|---|---|
| Class | Non-peptide ghrelin (GHS-R1a) agonist |
| Route | Oral |
| Half-life | ~24 hours |
| Typical research dose | 10–25 mg/day |
Reported half-life: ~24 hours.
MK-677 sits in our growth hormone support category. These are the other compounds in the same category, useful when you are deciding which reference page to read next.
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
This reference page was last reviewed on 2026-06-13 by the Clarity Wellness editorial team.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Technically no — it is a small-molecule ghrelin mimetic, but it is commonly grouped with peptides because it targets the same GH pathway.
Yes. Oral availability is one of its main research distinctions versus injectable secretagogues like Ipamorelin.